Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ingrid Hedenfalk

Showing results (31-40 of 67) with videos related to

Pageof 7
Sort By:
International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists|May 9, 2017
Claudin-4 Expression is Associated With Survival in Ovarian Cancer But Not With Chemotherapy ResponseLaura Martín de la Fuente, Susanne Malander, Linda Hartman, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|January 25, 2014
Nuclear HIF1A expression is strongly prognostic in sporadic but not familial male breast cancerSiddhartha Deb, Ida Johansson, David Byrne, et al.
Cancer Immunology, Immunotherapy : CII|January 3, 2025
Tertiary lymphoid structures in high-grade serous tubo-ovarian carcinoma: anatomical site mattersSofia Westbom-Fremer, Lena Tran, Anna Ebbesson, et al.
Virchows Archiv : an International Journal of Pathology|January 26, 2020
PD-1/PD-L1 expression and tumor-infiltrating lymphocytes are prognostically favorable in advanced high-grade serous ovarian carcinomaLaura Martin de la Fuente, Sofia Westbom-Fremer, Nicolai Skovbjerg Arildsen, et al.
Breast Cancer Research : BCR|February 16, 2012
Gene expression profiling of primary male breast cancers reveals two unique subgroups and identifies N-acetyltransferase-1 (NAT1) as a novel prognostic biomarkerIda Johansson, Cecilia Nilsson, Pontus Berglund, et al.
Molecular & Cellular Oncology|November 25, 2020
SOX2 is a promising predictor of relapse and death in advanced stage high-grade serous ovarian cancer patients with residual disease after debulking surgeryMaria Bååth, Sofia Westbom-Fremer, Laura Martin de la Fuente, et al.
Oncoimmunology|September 20, 2018
Dynamic evaluation of the immune infiltrate and immune function genes as predictive markers for neoadjuvant chemotherapy in hormone receptor positive, HER2 negative breast cancerAlexios Matikas, John Lövrot, Anna Ramberg, et al.
Cancer Letters|January 24, 2012
Co-targeting of the PI3K pathway improves the response of BRCA1 deficient breast cancer cells to PARP1 inhibitionSiker Kimbung, Ewa Biskup, Ida Johansson, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 1, 2003
Molecular classification of familial non-BRCA1/BRCA2 breast cancerIngrid Hedenfalk, Markus Ringner, Amir Ben-Dor, et al.
Genes|June 2, 2021
MET Expression and Cancer Stem Cell Networks Impact Outcome in High-Grade Serous Ovarian CancerMaria Bååth, Jenny-Maria Jönsson, Sofia Westbom Fremer, et al.
Pageof 7

Showing results (31-40 of 67) with videos related to

Sort By:
Pageof 7
International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists|May 9, 2017
Claudin-4 Expression is Associated With Survival in Ovarian Cancer But Not With Chemotherapy ResponseLaura Martín de la Fuente, Susanne Malander, Linda Hartman, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|January 25, 2014
Nuclear HIF1A expression is strongly prognostic in sporadic but not familial male breast cancerSiddhartha Deb, Ida Johansson, David Byrne, et al.
Cancer Immunology, Immunotherapy : CII|January 3, 2025
Tertiary lymphoid structures in high-grade serous tubo-ovarian carcinoma: anatomical site mattersSofia Westbom-Fremer, Lena Tran, Anna Ebbesson, et al.
Virchows Archiv : an International Journal of Pathology|January 26, 2020
PD-1/PD-L1 expression and tumor-infiltrating lymphocytes are prognostically favorable in advanced high-grade serous ovarian carcinomaLaura Martin de la Fuente, Sofia Westbom-Fremer, Nicolai Skovbjerg Arildsen, et al.
Breast Cancer Research : BCR|February 16, 2012
Gene expression profiling of primary male breast cancers reveals two unique subgroups and identifies N-acetyltransferase-1 (NAT1) as a novel prognostic biomarkerIda Johansson, Cecilia Nilsson, Pontus Berglund, et al.
Molecular & Cellular Oncology|November 25, 2020
SOX2 is a promising predictor of relapse and death in advanced stage high-grade serous ovarian cancer patients with residual disease after debulking surgeryMaria Bååth, Sofia Westbom-Fremer, Laura Martin de la Fuente, et al.
Oncoimmunology|September 20, 2018
Dynamic evaluation of the immune infiltrate and immune function genes as predictive markers for neoadjuvant chemotherapy in hormone receptor positive, HER2 negative breast cancerAlexios Matikas, John Lövrot, Anna Ramberg, et al.
Cancer Letters|January 24, 2012
Co-targeting of the PI3K pathway improves the response of BRCA1 deficient breast cancer cells to PARP1 inhibitionSiker Kimbung, Ewa Biskup, Ida Johansson, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 1, 2003
Molecular classification of familial non-BRCA1/BRCA2 breast cancerIngrid Hedenfalk, Markus Ringner, Amir Ben-Dor, et al.
Genes|June 2, 2021
MET Expression and Cancer Stem Cell Networks Impact Outcome in High-Grade Serous Ovarian CancerMaria Bååth, Jenny-Maria Jönsson, Sofia Westbom Fremer, et al.
Pageof 7